FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
ID: 344880Type: Posted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344880

Additional Information

https://grants.nih.gov/grants/guide/pa-files/PAR-23-072.html
Timeline
    Description

    The Food and Drug Administration (FDA) is offering a grant opportunity titled "FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)" aimed at facilitating high-quality conferences and scientific meetings that align with the FDA's public health mission. The program seeks to provide federal financial assistance for events such as symposia, workshops, and seminars, which are essential for exchanging information on topics impacting public health. With an estimated total program funding of $1,000,000 and an expected 20 awards, applicants must submit a Letter of Intent at least eight weeks prior to the application deadlines, which occur in April and October each year until 2025. For further inquiries, interested parties can contact Janelle Fundersburg at janelle.fundersburg@fda.hhs.gov or by phone at 301-798-2533.

    Files
    Title
    Posted
    PAR-23-072_ FDA Support for Conferences...pdf
    PAR-23-072_.pdf
    The file pertains to the process of issuing Requests for Proposals (RFPs) and federal grants at local and state levels, which are essential mechanisms for government entities to procure services or funding for various projects. It outlines the regulations, criteria, and procedures involved in creating and submitting RFPs to ensure transparency and fairness in the selection process. Furthermore, the document emphasizes the importance of compliance with both federal and state laws while managing funds and executing awarded contracts. It discusses key aspects such as eligibility, evaluation criteria, proposal submission guidelines, and reporting obligations for grant recipients. The primary goal of these RFPs and grants is to promote accountability, achieve strategic objectives, and drive community development through effective collaboration with private and non-profit sectors. Overall, the document serves as a foundational guide for stakeholders engaged in government funding processes, ensuring that projects align with public interest and regulatory requirements.
    PAR-23-072.html
    The U.S. Food and Drug Administration (FDA) has announced a Funding Opportunity Announcement (FOA) to support high-quality conferences and scientific meetings through the R13 Clinical Trial Not Allowed grant mechanism. This program aims to align with the FDA's public health mission by financially assisting events such as symposia and workshops. Applicants must secure advance permission to submit grant applications by sending a Letter of Intent at least eight weeks before the application due dates, scheduled for April and October each year until 2025. Funding levels vary by FDA components, with specific caps on total costs for different centers, including up to $250,000 for the Center for Biologics Evaluation and Research (CBER) and unlimited for the Center for Devices and Radiological Health (CDRH). The FOA emphasizes diversity and inclusion in conference planning and requires a detailed diversity plan to enhance participation from underrepresented groups. Applicants are advised to submit applications early to allow for error corrections before the deadline, as late submissions will not be accepted. The document outlines detailed eligibility requirements, application procedures, and review criteria that emphasize scientific merit, innovation, and appropriateness of the conference objectives.
    Similar Opportunities
    FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)" aimed at facilitating federal financial assistance for high-quality conferences and scientific meetings that align with the FDA's mission. The program seeks to support events such as symposiums, seminars, and workshops that focus on public health issues relevant to the FDA's objectives, with an estimated total program funding of $1,000,000 and approximately 30 awards expected. Interested applicants, specifically small businesses, should note that non-domestic entities are ineligible, and applications must be submitted before the conference start date to be considered for funding. For further inquiries, applicants can contact Janelle Fundersburg at Janelle.Fundersburg@fda.hhs.gov or by phone at 301-796-2533.
    Collaborations to Enhance Drug Development and Regulatory Science
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is inviting applications for a federal grant titled "Collaborations to Enhance Drug Development and Regulatory Science." This opportunity aims to establish cooperative agreements that support Public-Private Partnerships and collaborative activities under the Critical Path Initiative, focusing on innovative projects that enhance drug product development, advanced manufacturing, and the translation of scientific discoveries into therapeutics. The initiative is crucial for fostering innovation in drug safety, efficacy, quality, and performance, with a total funding ceiling of $5 million available for six expected awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call (240) 402-7610 for further information.
    NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Conference Grant (R13) to support high-quality scientific conferences that align with public health and the scientific missions of participating Institutes and Centers. This initiative encourages diverse participation and requires applicants to submit a detailed diversity plan, conference objectives, and logistical arrangements, while ensuring that costs align with actual project needs. The funding is crucial for fostering inclusive environments at scientific gatherings, with applications evaluated based on significance, innovation, approach, and diversity. Interested applicants can find more information and guidelines at the NIH website, with the application submission period opening on March 12, 2024, and closing on January 8, 2027. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Drug Development Tools Research Grants (U01) Clinical Trials Optional
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering Drug Development Tools Research Grants (U01) to support research aimed at advancing drug development tools (DDTs) that have an accepted or reviewable Letter of Intent within the FDA's qualification program. These grants are intended for developers working towards their qualification plan or full qualification package, focusing on tools that can enhance public health by optimizing the drug development process, such as biomarkers or animal models. The funding opportunity provides up to $500,000 for a maximum two-year period, with applications due by May 13, 2024, and May 13, 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov for further information and are encouraged to review the detailed announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-030.html.
    NIOSH Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
    Active
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering a grant opportunity titled "NIOSH Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)" aimed at supporting high-quality scientific meetings that advance research in occupational safety and health. Eligible applicants, including nonprofits without 501(c)(3) status and higher education institutions, are encouraged to submit proposals that align with NIOSH's strategic goals and the National Occupational Research Agenda (NORA), focusing on significant occupational health issues. This initiative underscores NIOSH's commitment to enhancing workplace safety through rigorous research and collaboration among experts, with a total funding amount of $500,000 available for up to five awards, each ranging from $10,000 to $20,000. Interested parties should submit their applications by December 15, 2025, and can contact Sharon Chou, Ph.D., at SChiou@cdc.gov for further information.
    Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) has announced a funding opportunity for clinical studies of orphan products addressing unmet needs in rare diseases through the Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) program. This initiative aims to support clinical trials that evaluate the safety and efficacy of products intended for rare diseases, with the goal of increasing the number of approved treatments and improving drug development for conditions affecting approximately 30 million Americans. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and for-profit entities, with grants available up to $650,000 per year for a maximum of four years. Interested parties should submit their applications by September 22, 2024, and can reach out to Shashi Malhotra at shashi.malhotra@fda.hhs.gov for further information.
    Critical Path Public Private Partnerships Clinical Trials Optional
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Critical Path Public Private Partnerships Clinical Trials Optional," aimed at supporting the continuation of existing consortia groups established by the Critical Path Institute. This initiative seeks applications to manage and maintain these groups, fostering innovative projects in research, education, and outreach to enhance drug product innovation and accelerate the development of therapeutics. The grant, which has an award ceiling and floor of $20 million, is expected to result in one award, with applications being accepted for the fiscal year 2024. Interested applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information.
    FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering the Health Equity Innovation Award (U01) to fund innovative research aimed at enhancing minority health and advancing health equity objectives. This funding opportunity focuses on proposals that promote diversity in clinical trials, improve data availability on diverse populations, and amplify the voices of underrepresented patient groups. With an award ceiling of $1 million and a floor of $250,000, the FDA anticipates making four awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.
    Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a federal grant opportunity titled "Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required." This grant aims to fund clinical trials that evaluate the efficacy and safety of products intended to address unmet needs in rare neurodegenerative diseases affecting both children and adults, thereby increasing the number of approved treatments in this critical area. The initiative is part of the FDA's broader effort to enhance drug development for rare diseases, which is vital for improving health outcomes in affected populations. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for more information, with funding amounts ranging from $650,000 to $900,000 for the fiscal year 2025.
    Development and Maintenance of Human and Animal Food Rapid Response Teams (U2F) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Development and Maintenance of Human and Animal Food Rapid Response Teams (U2F) Clinical Trials Not Allowed." This initiative aims to establish and sustain Rapid Response Teams (RRTs) to enhance the national integrated food safety system by coordinating federal, state, and local emergency response efforts related to human and animal food safety. The program is critical for improving regulatory and surveillance capabilities, ensuring rapid identification and removal of contaminated food, and fostering continuous improvement in response strategies. Interested applicants, including state governments and other entities, can apply for funding ranging from $360,000 to $1,440,000, with an expected four awards to be made. For further inquiries, applicants may contact Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610.